Literature DB >> 18377803

Microbial host interactions in IBD: implications for pathogenesis and therapy.

R Balfour Sartor1, Marcus Muehlbauer.   

Abstract

Crohn's disease (CD), ulcerative colitis (UC), and pouchitis appear to be caused by pathogenic T-cell responses to discrete antigens from the complex luminal microbiota, with susceptibility conferred by genetic polymorphisms that regulate bacterial killing, mucosal barrier function, or immune responses. Environmental triggers initiate or reactivate inflammation and modulate genetic susceptibility. New pathogenesis concepts include defective bacterial killing by innate immune cells in CD, colonization of the ileum in CD with functionally abnormal Escherichia coli that adhere to and invade epithelial cells and resist bacterial killing, and alterations in enteric microbiota composition in CD, UC, and pouchitis detected by molecular probes. The considerable therapeutic potential of manipulating the enteric microbiota in inflammatory bowel disease patients has not been realized, probably due to failure to recognize heterogenic disease mechanisms that require individualized use of antibiotics, probiotics, prebiotics, combination therapies, and genetically engineered bacteria to restore mucosal homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18377803     DOI: 10.1007/s11894-007-0066-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  130 in total

1.  Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.

Authors:  Koichi S Kobayashi; Mathias Chamaillard; Yasunori Ogura; Octavian Henegariu; Naohiro Inohara; Gabriel Nuñez; Richard A Flavell
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

2.  Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis.

Authors:  Uri Gophna; Katrin Sommerfeld; Sharon Gophna; W Ford Doolittle; Sander J O Veldhuyzen van Zanten
Journal:  J Clin Microbiol       Date:  2006-09-20       Impact factor: 5.948

Review 3.  Probiotic effects on inflammatory bowel disease.

Authors:  Barbara Sheil; Fergus Shanahan; Liam O'Mahony
Journal:  J Nutr       Date:  2007-03       Impact factor: 4.798

4.  ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach.

Authors:  G-T Ho; N Soranzo; E R Nimmo; A Tenesa; D B Goldstein; J Satsangi
Journal:  Hum Mol Genet       Date:  2006-01-24       Impact factor: 6.150

5.  Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease.

Authors:  Maria Mylonaki; Neil B Rayment; David S Rampton; Barry N Hudspith; Jonathan Brostoff
Journal:  Inflamm Bowel Dis       Date:  2005-05       Impact factor: 5.325

6.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Authors:  Marla C Dubinsky; Ying-Chao Lin; Debra Dutridge; Yoana Picornell; Carol J Landers; Sharmayne Farrior; Iwona Wrobel; Antonio Quiros; Eric A Vasiliauskas; Bruce Grill; David Israel; Ron Bahar; Dennis Christie; Ghassan Wahbeh; Gary Silber; Saied Dallazadeh; Praful Shah; Danny Thomas; Drew Kelts; Robert M Hershberg; Charles O Elson; Stephan R Targan; Kent D Taylor; Jerome I Rotter; Huiying Yang
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

8.  Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis.

Authors:  A-P Bai; Q Ouyang; X-R Xiao; S-F Li
Journal:  Int J Clin Pract       Date:  2006-03       Impact factor: 2.503

9.  Epithelial NEMO links innate immunity to chronic intestinal inflammation.

Authors:  Arianna Nenci; Christoph Becker; Andy Wullaert; Ralph Gareus; Geert van Loo; Silvio Danese; Marion Huth; Alexei Nikolaev; Clemens Neufert; Blair Madison; Deborah Gumucio; Markus F Neurath; Manolis Pasparakis
Journal:  Nature       Date:  2007-03-14       Impact factor: 49.962

10.  CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease.

Authors:  Nicolas Barnich; Frédéric A Carvalho; Anne-Lise Glasser; Claude Darcha; Peter Jantscheff; Matthieu Allez; Harald Peeters; Gilles Bommelaer; Pierre Desreumaux; Jean-Frédéric Colombel; Arlette Darfeuille-Michaud
Journal:  J Clin Invest       Date:  2007-05-24       Impact factor: 14.808

View more
  41 in total

1.  Bacillus subtilis-mediated protection from Citrobacter rodentium-associated enteric disease requires espH and functional flagella.

Authors:  Sara E Jones; Katherine L Knight
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 2.  Mucosal control of the intestinal microbial community.

Authors:  Sylvia Brugman; Edward E S Nieuwenhuis
Journal:  J Mol Med (Berl)       Date:  2010-06-04       Impact factor: 4.599

Review 3.  Crohn's disease: a clinical update.

Authors:  Francis Ha; Hanan Khalil
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

4.  Genetic deletion of Klf4 in the mouse intestinal epithelium ameliorates dextran sodium sulfate-induced colitis by modulating the NF-κB pathway inflammatory response.

Authors:  Amr M Ghaleb; Hamed Laroui; Didier Merlin; Vincent W Yang
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 5.  Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad.

Authors:  Maciej Chichlowski; Laura P Hale
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-16       Impact factor: 4.052

6.  Gut bacteria in health and disease.

Authors:  Eamonn M M Quigley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-09

Review 7.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

8.  Helicobacter bilis Infection Alters Mucosal Bacteria and Modulates Colitis Development in Defined Microbiota Mice.

Authors:  Todd Atherly; Curtis Mosher; Chong Wang; Jesse Hostetter; Alexandra Proctor; Meghan W Brand; Gregory J Phillips; Michael Wannemuehler; Albert E Jergens
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

Review 9.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

10.  FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice.

Authors:  Takashi Nishimura; Akira Andoh; Atsushi Nishida; Makoto Shioya; Yuhsuke Koizumi; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.